FIG. 4.

Recombinant CMV stimulation reveals broader target range of CMV-specific T cells in seropositive donors. Donor PBMC were stimulated with either AD169- or RV798-infected autologous fibroblasts and then expanded in vitro with the addition of recombinant IL-2 after 7 days. After 2 weeks, the cultures were restimulated and then, after another 7 days, tested for specificity by 5-h chromium release assays. The target cells were autologous LCLs infected overnight with MVAs at an MOI of 2:1. The effector/target ratios were 10:1 for the data shown.